Biotechnology News and Research

RSS

Drug registration process for Nutra Pharma's pain reliever begins

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

22 Sep 2009

Winners of the 2009 Biotechnology Vision Summit's Emerging Company Showcase announced

Six Wisconsin biotechnology companies have been selected the winners of the first Emerging Company Showcase. The showcase is part of the Biotechnology Vision Summit 2009, being held on Wednesday, Oct. 7, at the Madison Marriott West in Madison, Wis. The summit and the showcase are being hosted by BioForward, the member-driven state association that is the voice of Wisconsin’s biotechnology industry.

22 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

U.S. HHS orders for an additional 29 million doses of MedImmune's influenza vaccine

MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million.

22 Sep 2009

Cell Therapeutics announces that it has been added to the NASDAQ OMX Global Biotechnology Index

Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: QGBI). Component changes to the index occurred prior to the market open on September 21, 2009.

22 Sep 2009

New device for identifying eye conditions in infants

Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.

22 Sep 2009

GeoVax requests FDA meeting to discuss IND for its therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that it has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss a proposed IND for GeoVax's therapeutic vaccine as a treatment for individuals infected with HIV/AIDS.

22 Sep 2009

Researcher can anticipate immune response in Alzheimer's patients

A researcher who is working on a vaccine for Alzheimer's disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients. This continuing research at Ben-Gurion University of the Negev could one day lead to specific Alzheimer's vaccines that reduce plaque, neuronal damage and inflammation associated with the disease.

22 Sep 2009

New device could be the solution to menstrual pain

While most women experience minor pain during menstruation, for others, the pain can be severe enough to interfere with everyday activities and require medication. New research to be presented at the 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will reveal initial findings of safety surrounding a new device that may more effectively treat menstrual pain.

22 Sep 2009

Dalton Pharma expands pharmaceutical manufacturing services

Dalton Pharma Services is pleased to announce the expansion of its pharmaceutical manufacturing services by adding Formulation Development to its list of integrated capabilities.

22 Sep 2009

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Neurodegenerative disorders called frontotemporal dementias (FTD) are the second-leading cause of early-onset dementia in persons under age 65 and can emerge sometimes as early as age 20.

21 Sep 2009

Primeradx raises funds for commercialization of their technology

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has closed on its $20 million Series C financing. The financing was led by CHL Medical Partners and also included significant participation by many of the Company’s existing investors; Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Company and the Invus Group.

21 Sep 2009

U.S. Department of Health & Human Services requests BioCryst for proposal for peramivir supply

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received a request for proposal (RFP) from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA).

21 Sep 2009

HHS awards $77.2 million contract to BioCryst to complete Phase 3 development of peramivir

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been awarded a $77.2 million contract modification by the U.S. Department of Health & Human Services (HHS) to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous (i.v.) peramivir, for the treatment of complicated influenza.

21 Sep 2009

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

21 Sep 2009

No communication to workers from employers about policies in the workplace pertaining to H1N1: Study

Most workers have not had any direction from their employers about the upcoming flu season, according to a national survey released today by Mansfield Communications Inc.

21 Sep 2009

Ontarians support research involving biotechnology

Ontarians overwhelmingly value biotechnology’s contribution to their lives and the economy, BIOTECanada told Minister Milloy and an audience of over 150 business leaders at the launch of the sixth annual National Biotechnology Week.

21 Sep 2009

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).

21 Sep 2009

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

21 Sep 2009

SHP-2 protein molecule encourages placenta growth

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have shown that a common biological protein molecule called SHP-2 is crucial for encouraging placenta growth. The research is published today in Endocrinology.

21 Sep 2009

Biotechnology News and Research

Drug registration process for Nutra Pharma's pain reliever begins

Winners of the 2009 Biotechnology Vision Summit's Emerging Company Showcase announced

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

U.S. HHS orders for an additional 29 million doses of MedImmune's influenza vaccine

Cell Therapeutics announces that it has been added to the NASDAQ OMX Global Biotechnology Index

New device for identifying eye conditions in infants

GeoVax requests FDA meeting to discuss IND for its therapeutic HIV/AIDS vaccine

Researcher can anticipate immune response in Alzheimer's patients

New device could be the solution to menstrual pain

Dalton Pharma expands pharmaceutical manufacturing services

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Primeradx raises funds for commercialization of their technology

U.S. Department of Health & Human Services requests BioCryst for proposal for peramivir supply

HHS awards $77.2 million contract to BioCryst to complete Phase 3 development of peramivir

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

No communication to workers from employers about policies in the workplace pertaining to H1N1: Study

Ontarians support research involving biotechnology

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

SHP-2 protein molecule encourages placenta growth

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News